On June 05 2018,Simcere had a wonderful night with honorable guests and potential partners at Harvard.

Mr. Jinsheng Ren, Founder& Chairman of Simcere spoke at Nanjing Innovation & High Tech Industries Promotion seminar in Boston.

According to the database of the SFDA， "Biqi®-Montmorillonite Powder" manufactured by Simcere Pharmaceutical (Hainan) Co., Ltd. is among the first batch of montmorillonite powder products to have passed the SFDA's Quality Consistency Evaluation for Generic Drugs.

On the World Lab Animal Day today, let’s extend our sincere gratitude for all the lab animals. Every life is precious and should be respected. #SincereGratitudeFromSimcere

Another milestone in the battle against Covid-19, as Wuhan reported ZERO #coronavirus patients under hospitalization. #keep calm and battle on

According to the Top 200 Pharmaceuticals by Retail Sales in 2019, China’s strength is playing an increasingly important role. Simcere will continue to strive for the future to allow patients with better medicines sooner.

The once enveloping haze will clear up eventually. Salute to all the white angels battling against the virus. Thank you to your great endeavors.

Every step counts towards the final launch of a successful vaccination.

On May 15, 2020, Simcere announced that key clinical data from a strategic cooperation on KN035, also known as Envafolimab, will be released at the upcoming annual meeting of ASCO 2020 in the US. en.simcere.com/Index/news_det…

The World Health Organization has temporarily paused hydroxychloroquine study due to safety concerns. General Secretary Tedros Adhanom Ghebreyesus made the announcement yesterday. #COVID-19 #WHO

Studies have shown that COVID-19 outbreaks tend to be shorter and smaller when genomics is used in help contact tracing. Experts believe genomics will be crucial in the outbreak control.

Simcere Dongyuan is awarded the "Jiangsu Province Quality Award 2017",the supreme quality award in Jiangsu Province issued by the provincial government to organizations that implement excellent performance management and achieve significant economic and social benefits.

On January 9, 2018， the Medical Doctor Weekly Summit 2018 was held in Beijing. During the event, the well known medicine publication announced several industrial awards. Simcere is listed among 2017 Driving Force of the Industry • Top 10 Pharmaceutical Pioneer

March 26, 2018 – Agena Bioscience and Simcere Diagnostics announced the signing of a strategic partnership agreement focusing on expanding the use of Agena’s MassARRAY® System for companion diagnostics and pharmacogenetic testing in China.

On March 28, Simcere announced the official establishment of Simcere Innovation Center on the company‘’s 23rd anniversary. The Simcere Innovation Center, which is currently building offices in Shanghai and Boston aims to build a sustainable development engine for the company.

On April 9 2018, Shaanxi and Jiangsu Top Provincial Leadership Team Went On Inspection Tour In Simcere Headquater

On Apr 20, 2018, Simcere Pharmaceutical Group and HitGen Ltd announced that they have entered into a license agreement on innovative drug discovery by utilizing the DNA encoded libraries of HitGen. For more information, please visit simcere.com

On April 22, CSCO Guidelines on the Diagnosis & Treatment of Conventional Osteosarcoma (2018) was formally released. Endostar, Simcere’s biological oncology drug is included in the 1st line recommendation for pre-operative treatment of stage IIB/III Osteosarcoma.

May 21, 2018, the executive team of Merus visited the headquarter of Simcere. During meeting with Simcere’s Chairman Mr Jinsheng Ren and Simcere’s scientists team, both companies exchanged information on the recent development and discussed possibility for future collaboration.

Dear Friends, This is our sincere invitation to a night of fun event at Boston US on 5th of June 2018 for you to know Simcere better. Please scan the QR code to resister for 2018 CABA/CBA Biopharma Forum-“Simcere Night”， join us over exciting lectures and a pleasant dinner.